Addendum to the Technology License Agreement between The Research Foundation of State University of New York for and on behalf of University at Buffalo and Donald D. Hickey, M.D. and Clas E. Lundgren, M.D., Ph.D. and Scivanta Medical Corporation
EXHIBIT
10.18
Addendum
to the Technology License Agreement
between
The
Research Foundation of State University of New York
for
and on behalf of University at Buffalo
and
Xxxxxx
X. Xxxxxx, M.D.
and
Clas
X. Xxxxxxxx, M.D., Ph.D.
and
Scivanta
Medical Corporation
This
Addendum to the Technology License Agreement (this “Agreement”) is entered into
this 29th day of June, 2007 (the “Effective Date”) by and between The Research
Foundation of State University of New York, for and on behalf of University
at
Buffalo, a non-profit corporation organized and existing under the laws of
the
State of New York (the “Foundation”), Xxxxxx X. Xxxxxx, M.D. (“Xxxxxx”) and Clas
X. Xxxxxxxx, M.D., Ph.D. (a/k/a Xxxxx Xxxxxxxx and referenced herein as
“Xxxxxxxx”) and Scivanta Medical Corporation (formerly Medi-Hut Co., Inc.), a
corporation duly organized under the laws of the State of Nevada, and having
its
principal place of business at 000 Xxxxxx Xxxxxx, Xxxxxx Xxxx, Xxx Xxxxxx 00000
(“Licensee”). Foundation, Xxxxxx and Xxxxxxxx will be collectively referenced
herein as “Licensor”.
WHEREAS,
Licensor and Licensee entered into an exclusive Technology License Agreement
on
November 10, 2006, to facilitate the development and commercialization of
certain technology owned by Licensor so that this technology may be utilized
to
the fullest extent for the benefit of Licensee, Licensor, the inventor(s) and
the public;
WHEREAS,
Licensor has or will enter into a “Research Agreement” and a “Manufacturing
License Agreement” with Ethox International, Inc. (“Ethox”) to further
facilitate the development and commercialization of the licensed technology
(“Scivanta Ethox Agreements”);
WHEREAS,
Licensee has or will enter into a “Project Development Agreement” and a “Supply
Agreement” with Ethox (the “Scivanta Ethox Agreements”) to set forth the terms
and conditions under which Ethox shall engineer, develop and manufacture key
components of the Xxxxxx Cardiac Monitoring System (“HCMS”);
WHEREAS,
Licensor and Licensee desire to modify the aforementioned Technology License
Agreement for the mutual benefit of both parties;
NOW,
THEREFORE, in consideration of the mutual promises and covenants contained
herein and good and valuable consideration, the receipt of which is hereby
acknowledged, the parties agree as follows:
1. |
The
modifications of the Technology License Agreement herein will be
effective
as of the Effective Date and will remain in effect for the duration
of the
Technology License Agreement unless further modified in writing by
the
parties hereto.
|
2. |
Section
2.1 of the Technology License Agreement will be replaced
with:
|
2.1 Exclusive
License. Licensor
grants to Licensee an exclusive license under its Technology rights to (a)
develop, make, have made, use, sell and offer for sale or otherwise exploit
the
Licensed Products, and (b) use and reproduce Software, create Derivatives,
and
distribute Software to end-users through the normal channels of distribution,
in
the Field and Territory during the Term. Licensee will have the unrestricted
right to develop Licensee Improvements relating to the Licensed Products in
the
United States for distribution and exploitation of the Licensed Products either
in the United States or outside of the United States. Licensee will also have
the unrestricted right to develop Licensee Improvements relating to the Licensed
Products in any foreign country for distribution and exploitation of the
Licensed Products in any other country, including the U.S. Notwithstanding
the
exclusive license granted to Licensee, Licensee hereby consents to Licensor’s
grant of a limited, non-exclusive license to Ethox for the sole purpose of
the
engineering, development and manufacture of the catheter component of the Xxxxxx
Cardiac Monitoring System (“HCMS”) in accordance with the Scivanta Ethox
Agreements. Licensor and Licensee agree that such limited licensed rights will
be granted only to Ethox under a separate manufacturing license agreement
(“Ethox Agreement”) and no other party. If for any reason the Ethox Agreement or
the Scivanta Ethox Agreements are terminated or expire, the limited license
granted to Ethox hereunder will immediately terminate and all exclusive license
rights will remain with Licensee.
3. |
Section
6.1 of the Technology License Agreement will be amended to change
the
November 1, 2008, Payment Amount to Xxxxxx and Xxxxxxxx from $109,578
to
$108,235.
|
4. |
Other
than as specifically modified in this Addendum, all other terms,
conditions and covenants of the Technology License Agreement entered
into
on November 10, 2006 shall remain in full force and
effect.
|
2
IN
WITNESS WHEREOF, the undersigned duly authorized representatives of the parties
have executed this Agreement, effective on the date first written
above.
SCIVANTA
MEDICAL CORPORATION
|
THE
RESEARCH FOUNDATION OF
|
STATE
UNIVERSITY OF
|
|
NEW
YORK
|
|
By:
/s/ Xxxxx X.
XxXxxxx
|
By:
/s/ Xxxxxxx
Xxxxxxx
|
Xxxxx X. XxXxxxx
|
Xxxxxxx Xxxxxxx
|
Title:
President and Chief Executive Officer
|
Title:
Assistant Vice Xxxxxxx, STOR
|
Date:
June 29, 2007
|
Date:
June 29, 2007
|
XXXXXX
X. XXXXXX, M.D.
|
CLAS
X. XXXXXXXX, M.D., Ph.D.
|
By:
/s/ Xxxxxx X. Xxxxxx,
M.D.
|
By:
/s/ Clas X. Xxxxxxxx, M.D.,
Ph.D.
|
Xxxxxx X. Xxxxxx, M.D.
|
Clas X. Xxxxxxxx, M.D., Ph.D.
|
Date:
June 29, 2007
|
Date:
June 29, 2007
|
3